

(51) International Patent Classification:
C07K 14/54 (2006.01) A61K 38/20 (2006.01)

(21) International Application Number:
PCT/US2024/032147

(22) International Filing Date:
31 May 2024 (31.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/505,651 01 June 2023 (01.06.2023) US

(71) Applicant: SYNTHKINE, INC. [US/US]; 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(72) Inventors: MORIN, Andrew; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). PETOJEVIC, Tatjana; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). RAMADASS, Mahalakshmi; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US). JAYARAMAN, Bhargavi; c/o Synthekine, Inc., 1505 O'Brien Drive, Suite D, Menlo Park, California 94025 (US).

(74) Agent: HINSCH, Matthew E. et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, Suite 2800, Atlanta, Georgia 30309 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: IL10 INVERTED MONOMERS




FIG. 1

(57) Abstract: The present disclosure relates to engineered polypeptides comprising components of IL10 molecules that modulate signal transduction associated with IL10 and methods of use thereof. In some aspects, the polypeptides of the disclosure exhibit cell type biased activity. In some aspects the polypeptides of the disclosure substantially retain the anti-inflammatory properties of IL10 but have significantly diminished pro-inflammatory properties of IL-10. The disclosure provides methods of use of the engineered polypeptides in the treatment of disease.

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*